Pluri Inc. (TLV:PLUR)

Market Cap	129.69M
Revenue (ttm)	3.85M
Net Income (ttm)	-77.13M
Shares Out	n/a
EPS (ttm)	-13.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,271
Average Volume	3,773
Open	1,607.00
Previous Close	1,607.00
Day's Range	1,580.00 - 1,657.00
52-Week Range	1,299.00 - 2,345.00
Beta	n/a
RSI	38.57
Earnings Date	Sep 12, 2025

About Pluri

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 118
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: PLUR

Financial Performance

In 2024, Pluri's revenue was $326,000, an increase of 13.59% compared to the previous year's $287,000. Losses were -$20.89 million, -26.25% less than in 2023.

Financial numbers in USD